Navigation Links
NMB's Fans and Blowers to be Represented in Canada by CST-Arwin
Date:11/3/2008

ing assemblies, keyboards and audio speakers. NMB products can be found in the personal computing, networking, telecommunications, home entertainment, home electronics, automotive, and medical and industrial markets.

For more information on NMB Technologies Corporation, please visit: http://www.nmbtc.com or e-mail us at info @ nmbtc.com

About CST-Arwin - CST-Arwin is a well known and respected manufacturer's representative company serving the electronic industry across Canada. CST-Arwin's primary focus is on the electro-mechanical product and thermal management solutions. CST-Arwin has offices in Toronto, Montreal and Vancouver.

For more information on CST-Arwin, please visit: http://www.cstarwin.com or reach them by e-mail at sales @ cstarwin.com

NMB Technologies Corporation
A Minebea Group Company
9730 Independence Avenue
Chatsworth, California 91311   
Tel: 818.341.3355 Fax: 818.341.8207

Press Contact:
Sarah deRosier
Marcom Manager
sderosier @ nmbtc.com
818-341-3355 Ext. 3406

# # #

Read the full story at http://www.prweb.com/releases/NMB/axial_fan_and_blower/prweb1555674.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

0

GOOD

Page: 1 2

Related medicine news :

1. Founding Father of Modern Cosmetic Dermatology Seeks to Warn Public of Misrepresented Data and Inappropriate Use of Botox
2. Berkery Noyes Represented The Riverside Company on the Sale of HCPro Holdings, Inc. to Halyard Capital, LLC
3. Pulmonary Fibrosis Patients/9/11 Responders Represented at State of the Union Address for Second Year in a Row
4. Telehealth Solutions from American TeleCare, Inc. Support Heart Failure Management Study in Canada
5. Growth Rate of U.S. Giving for Health Care Falls More Than 50 Percent in 2007 But Rises Almost Threefold in Canada, According to Association for Healthcare Philanthropys Annual Report on Giving
6. Worlds First Cattle Vaccine to Reduce E. coli O157 Threat Receives Full Licensing Approval in Canada
7. Ocean Nutrition Canada Limited Secures Their Position as the Largest Omega-3 EPA/DHA Ingredient Supplier in the World
8. Colds and flu cut by one-third in study of Canadas top cold fighter in vaccinated seniors
9. MDS Commences Arbitration against AECL over Cancelled MAPLE Project and Files $1.6 Billion Court Claim against AECL and the Government of Canada
10. Pioneering stroke researcher awarded Canadas highest honor
11. First CyberKnife System to be Installed in Canada
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
NMB's Fans and Blowers to be Represented in Canada by CST-Arwin
NMB's Fans and Blowers to be Represented in Canada by CST-Arwin
Breaking Medicine News(10 mins):Health News:Case Western Reserve to receive $19.7m to study tuberculosis treatment drugs 2Health News:Reportlinker Adds Mesenchymal Stem Cells, Advances & Applications 2Health News:Reportlinker Adds Mesenchymal Stem Cells, Advances & Applications 3Health News:Reportlinker Adds Mesenchymal Stem Cells, Advances & Applications 4Health News:New York Women's Agenda Presents AUA Foundation Executive Director Sandra Vassos with Star Award 2Health News:New York Women's Agenda Presents AUA Foundation Executive Director Sandra Vassos with Star Award 3Health News:Leading Orthopaedic Surgeon Thomas A. Einhorn Offers Breakthrough Non-Embryonic Stem Cell Surgery to Reverse Early Necrosis of the Hip 2Health News:Leading Orthopaedic Surgeon Thomas A. Einhorn Offers Breakthrough Non-Embryonic Stem Cell Surgery to Reverse Early Necrosis of the Hip 3Health News:Leading Orthopaedic Surgeon Thomas A. Einhorn Offers Breakthrough Non-Embryonic Stem Cell Surgery to Reverse Early Necrosis of the Hip 4Health News:The National Blue Cross and Blue Shield Association Selects ATTUS Technologies as Preferred Provider for OFAC, OIG, EPLS and USA PATRIOT Act Compliance 2Health News:The National Blue Cross and Blue Shield Association Selects ATTUS Technologies as Preferred Provider for OFAC, OIG, EPLS and USA PATRIOT Act Compliance 3
Breaking Medicine Technology:Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 2Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 3Seven New Biopharmaceutical Research Companies Join PhRMA's Mission to Advance Medical Innovation 4Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 2Biomatrica Launches DNAgard(TM) for Room Temperature Storage of Tissues and Cell Culture 3Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 2Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 3Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 4Data Published in Muscle and Nerve Validates the Six-Minute Walk Test as an Outcome Measure in Duchenne Muscular Dystrophy 5Childrens Hospitals and Clinics of Minnesota Launches H1N1 Outreach Effort with Minneapolis and Saint Paul Public Schools 58019 1Childrens Hospitals and Clinics of Minnesota Launches H1N1 Outreach Effort with Minneapolis and Saint Paul Public Schools 58019 2Childrens Hospitals and Clinics of Minnesota Launches H1N1 Outreach Effort with Minneapolis and Saint Paul Public Schools 58019 3Revolutionary Drug Could Be New Hope for Adrenal Cancer Patients 58017 1Revolutionary Drug Could Be New Hope for Adrenal Cancer Patients 58017 2Revolutionary Drug Could Be New Hope for Adrenal Cancer Patients 58017 3Revolutionary Drug Could Be New Hope for Adrenal Cancer Patients 58017 4Revolutionary Drug Could Be New Hope for Adrenal Cancer Patients 58017 5ScienceFirst Staff Expansion 58015 1
Other Medicine Technology:Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 2Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 3Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 4Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 5Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 7Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 8Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 9Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 10InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL) 2InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL) 3InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL) 4InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL) 5